Filing Summary
Entity and period: The supplied filing is Apollo Medical Holdings, Inc.’s Form 10-K for the fiscal year ended January 31, 2013, with comparative results for the year ended January 31, 2012. This does not match the request metadata identifying Astrana Health, Inc. or a 2012 Q4 period. The filing includes unaudited quarterly results for the quarter ended January 31, 2013.
Business Context
Apollo Medical operated a California physician-centered healthcare delivery and management business serving Medicare, commercial and Medi-Cal beneficiaries. It provided hospitalist and related services at 28 hospitals and long-term acute-care facilities and reported a physician network of more than 300. About 89% of fiscal 2013 revenue was contracted revenue. In 2012, its ACO was selected to participate in CMS’s Medicare Shared Savings Program.
Financial Results and Liquidity
| Metric | FY ended Jan. 31, 2013 | FY ended Jan. 31, 2012 |
|---|---|---|
| Revenue | $7.776 million | $5.111 million |
| Gross profit | $1.460 million | $0.978 million |
| Gross margin | 18.8% | 19.1% |
| Operating expenses | $3.538 million | $1.392 million |
| Operating loss | $2.078 million | $0.413 million |
| Net loss | $8.905 million | $0.720 million |
| Basic and diluted loss per share | $0.27 | $0.02 |
| Cash from operating activities | $57,956 | Cash used: $385,455 |
Revenue rose 52.2%, attributed to new hospital contracts, same-market growth, expanded services, the VMM acquisition and a full year of PCCM operations. Gross margin edged down as cost of services grew slightly faster than revenue. General and administrative expense increased 155.1%, including higher stock-based compensation, consulting and professional fees, ACO-related costs and staffing. The filing attributes much of the larger operating loss to stock-based compensation, which totaled approximately $2.062 million for the year.
The audited statements report a $5.854 million loss from changes in fair value of derivative liabilities and $930,176 in interest expense. The derivative-related charge was noncash and followed the reclassification of the related instruments to equity after debt and warrant amendments. Cash and cash equivalents were $1.177 million at year-end, versus $164,361 a year earlier. Current assets were $2.872 million and current liabilities $1.705 million. Total debt was $2.875 million before $370,286 of debt discount; reported net debt was $2.504 million. Stockholders’ deficit was $391,379.
Audited cash flows show $31,685 used in investing activities and $986,095 provided by financing activities, including proceeds from notes and convertible notes, partly offset by $400,000 in distributions to a non-controlling interest. The filing contains inconsistent cash-flow figures in its MD&A: it also cites $152,751 of operating cash flow and $31,865 of investing cash use. The audited statements report $57,956 and $31,685, respectively.
Material Changes, Outlook and Risks
- The company raised $880,000 in 9% convertible notes on January 31, 2013; it reported net proceeds of approximately $776,000. The notes mature February 15, 2016, are convertible at $0.40 per share, and were issued with warrants.
- Management stated that operating losses might continue throughout fiscal 2014 and that available liquidity might not support operations for the next 12 months. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management planned to seek additional capital; it cautioned that failure to obtain it could force the company to cease operations.
- The ACO opportunity requires investment before any potential shared-savings revenue, and the company said substantial additional capital could be needed. Future results depend in part on the ACO program, reimbursement policy, provider participation and execution of growth plans.
- Healthcare regulation, Medicare and Medicaid reimbursement changes, payer audits and collection delays, medical malpractice claims, customer concentration, acquisition integration and dependence on key personnel were identified as risks. One customer represented 22% of fiscal 2013 revenue, down from 34% in fiscal 2012.
- Management identified material weaknesses in financial reporting controls: lack of written control documentation, insufficient segregation of accounting duties, and inadequate review and supervision. Management said remediation was underway; the independent auditor did not attest to internal control effectiveness.
- The company reported routine pending or threatened legal matters, primarily malpractice claims, and said their resolution was not expected to have a material adverse effect, while noting outcomes could not be predicted. It also disclosed that it had not yet adopted a formal ethics code.
Important Facts to Verify
- Confirm the intended issuer and period: the source filing is Apollo Medical Holdings, Inc.’s FY 2013 10-K, not a filing labeled Astrana Health or 2012 Q4.
- Reconcile the MD&A cash-flow figures with the audited statement of cash flows.
- Review liquidity forecasts, debt maturities and terms, and the company’s ability to raise additional capital in light of the going-concern warning.
- Assess the scale and potential dilution from stock awards, options, warrants and convertible notes; shares outstanding increased to 34.84 million from 29.34 million.
- Evaluate progress in remediating the disclosed material weaknesses and the concentration of revenue among major customers.